Last reviewed · How we verify
Zatolmilast/ BPN14770
At a glance
| Generic name | Zatolmilast/ BPN14770 |
|---|---|
| Sponsor | Tetra Discovery Partners |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome (PHASE2, PHASE3)
- Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) (PHASE2)
- An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome (PHASE3)
- A Study to Assess the Effects of BPN14770 on Rosuvastatin (PHASE1)
- A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zatolmilast/ BPN14770 CI brief — competitive landscape report
- Zatolmilast/ BPN14770 updates RSS · CI watch RSS
- Tetra Discovery Partners portfolio CI